2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 270 | - | - | ||
| 14 | - | - | ||
| 3 000 | - | - | ||
| 288 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenI can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
16 t sitten16 t sittenTämä julkaisu on poistettu.·11 t sittenBagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.- ·1 päivä sittenWatch or re-watch the annual report for 2025 https://www.youtube.com/watch?v=4OXikYWJ13g·1 päivä sitten · MuokattuGood to see management agrees with my assessment that BP should in no way look at India as a new market under current circumstances. Then management again mentions the forbidden word, "emission", when possibilities for capital raising are discussed. Emission is thus not off the table, even though the word is despised here on Nordnet.
- ·1 päivä sittenNotice convening the Annual General Meeting in Bioporto A/S https://www.globenewswire.com/news-release/2026/03/26/3262779/0/en/Notice-convening-the-Annual-General-Meeting-in-BioPorto-A-S.html
- ·1 päivä sitten · MuokattuThought-provoking. Management writes: "For 2026 BioPorto expects the US market for NGAL through Research Use Only (RUO) will continue to be the main growth driver." Thus, management does not currently expect "real" sales for clinical use to pick up in 2026, but that sales for "research" will continue to drive marginal low growth. I wonder if 3D gets that?·19 t sittenShareville is packed with small investors who think stock trading is just a competition about who can send the most romantic posts. The more hype they write, the more they believe the stock will rise. We have also seen this in Brain+, in SR and it is now on its way in Stenocare, which is 3ds' new darling. I'm familiar with that part, right from when bioporto was the most talked about, read most hyped, on euroinvestor. And the management is good at fueling that hype even with rhetoric that is in direct contradiction to the tools they deliver. But the small investors neither read nor understand those financial statements either. Perhaps because it has been buried under all the contentless hype, or perhaps it's just too long ago that the discussion here was about ngal, but I don't recall having read good critical posts about the product itself. I thought it could do more than it clearly can. I have (been) wrong about that. On the other hand, even though I still don't quite understand what the problem with ngal is, I have long since realized and accepted what the market tells me, namely that there is no demand for the product.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenI can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
- 16 t sitten16 t sittenTämä julkaisu on poistettu.·11 t sittenBagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.
- ·1 päivä sittenWatch or re-watch the annual report for 2025 https://www.youtube.com/watch?v=4OXikYWJ13g·1 päivä sitten · MuokattuGood to see management agrees with my assessment that BP should in no way look at India as a new market under current circumstances. Then management again mentions the forbidden word, "emission", when possibilities for capital raising are discussed. Emission is thus not off the table, even though the word is despised here on Nordnet.
- ·1 päivä sittenNotice convening the Annual General Meeting in Bioporto A/S https://www.globenewswire.com/news-release/2026/03/26/3262779/0/en/Notice-convening-the-Annual-General-Meeting-in-BioPorto-A-S.html
- ·1 päivä sitten · MuokattuThought-provoking. Management writes: "For 2026 BioPorto expects the US market for NGAL through Research Use Only (RUO) will continue to be the main growth driver." Thus, management does not currently expect "real" sales for clinical use to pick up in 2026, but that sales for "research" will continue to drive marginal low growth. I wonder if 3D gets that?·19 t sittenShareville is packed with small investors who think stock trading is just a competition about who can send the most romantic posts. The more hype they write, the more they believe the stock will rise. We have also seen this in Brain+, in SR and it is now on its way in Stenocare, which is 3ds' new darling. I'm familiar with that part, right from when bioporto was the most talked about, read most hyped, on euroinvestor. And the management is good at fueling that hype even with rhetoric that is in direct contradiction to the tools they deliver. But the small investors neither read nor understand those financial statements either. Perhaps because it has been buried under all the contentless hype, or perhaps it's just too long ago that the discussion here was about ngal, but I don't recall having read good critical posts about the product itself. I thought it could do more than it clearly can. I have (been) wrong about that. On the other hand, even though I still don't quite understand what the problem with ngal is, I have long since realized and accepted what the market tells me, namely that there is no demand for the product.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 270 | - | - | ||
| 14 | - | - | ||
| 3 000 | - | - | ||
| 288 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
UUTTA
2 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenI can understand that there are several who are not aware of why the NGAL test for children has been approved before the NGAL test for adults. The short version is that the previous management tried to get a test approved that would apply to both children and adults. The FDA would not approve that, so therefore the condition for an approval was that the test should be divided into children and adults, as it is now. The FDA also demanded that it should be the children's test that should be approved first and then for adults. It is entirely up to the FDA how and in what way it should proceed, and it is also up to the FDA how long it takes. They have some objectives for deadlines; whether they meet them is up to the FDA.
- 16 t sitten16 t sittenTämä julkaisu on poistettu.·11 t sittenBagerbrød Thanks for an, as usual, interesting dialogue. If you don't want posts deleted, then the best recommendation is that you maintain an objective angle and don't spice it up with irrelevant angles, such as other debaters "painting a gloomy picture". Now 3D is on the scene with something similar, and wants to focus on the world being unfair and NN not supporting 3D's desired censorship. Can't you @Bager, suggest to 3D that he mans up and actively participates in the debate and accepts that questions are asked when participating in a discussion forum. With wishes for a good weekend from here.
- ·1 päivä sittenWatch or re-watch the annual report for 2025 https://www.youtube.com/watch?v=4OXikYWJ13g·1 päivä sitten · MuokattuGood to see management agrees with my assessment that BP should in no way look at India as a new market under current circumstances. Then management again mentions the forbidden word, "emission", when possibilities for capital raising are discussed. Emission is thus not off the table, even though the word is despised here on Nordnet.
- ·1 päivä sittenNotice convening the Annual General Meeting in Bioporto A/S https://www.globenewswire.com/news-release/2026/03/26/3262779/0/en/Notice-convening-the-Annual-General-Meeting-in-BioPorto-A-S.html
- ·1 päivä sitten · MuokattuThought-provoking. Management writes: "For 2026 BioPorto expects the US market for NGAL through Research Use Only (RUO) will continue to be the main growth driver." Thus, management does not currently expect "real" sales for clinical use to pick up in 2026, but that sales for "research" will continue to drive marginal low growth. I wonder if 3D gets that?·19 t sittenShareville is packed with small investors who think stock trading is just a competition about who can send the most romantic posts. The more hype they write, the more they believe the stock will rise. We have also seen this in Brain+, in SR and it is now on its way in Stenocare, which is 3ds' new darling. I'm familiar with that part, right from when bioporto was the most talked about, read most hyped, on euroinvestor. And the management is good at fueling that hype even with rhetoric that is in direct contradiction to the tools they deliver. But the small investors neither read nor understand those financial statements either. Perhaps because it has been buried under all the contentless hype, or perhaps it's just too long ago that the discussion here was about ngal, but I don't recall having read good critical posts about the product itself. I thought it could do more than it clearly can. I have (been) wrong about that. On the other hand, even though I still don't quite understand what the problem with ngal is, I have long since realized and accepted what the market tells me, namely that there is no demand for the product.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 270 | - | - | ||
| 14 | - | - | ||
| 3 000 | - | - | ||
| 288 | - | - |
Välittäjätilasto
Dataa ei löytynyt